上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
MMAF sodium (Synonyms: Monomethylauristatin F sodium)
MMAF sodium (Monomethylauristatin F sodium) 是一种有效的微管蛋白聚合 (tubulin polymerization) 抑制剂,用作抗肿瘤药物。MMAF sodium (Monomethylauristatin F sodium) 广泛用作抗体偶联药物 (ADCs) 的细胞毒性成分,如Vorsetuzumab mafodotin 和 SGN-CD19A。
MMAF sodium Chemical Structure
CAS No. : 1799706-65-2
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
Free Sample (0.1-0.5 mg) | Apply now | ||
5 mg | ¥800 | In-stock | |
10 mg | ¥1200 | In-stock | |
25 mg | ¥1800 | In-stock | |
50 mg | ¥2500 | In-stock | |
100 mg | ¥3400 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
MMAF sodium 相关产品
•相关化合物库:
- Bioactive Compound Library Plus
- Toxins for Antibody-Drug Conjugate Research Library
生物活性 |
MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A[1][2][3]. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target |
|
||||||||||||||||
体外研究 (In Vitro) |
MMAF inhibits anaplastic large cell lymphoma Karpas 299, breast carcinoma H3396, renal cell carcinoma 786-O and Caki-1 cells with IC50s of 119, 105, 257 and 200 nM in vitro cytotoxicity assay[4]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
分子量 |
753.94 |
||||||||||||||||
Formula |
C39H64N5NaO8 |
||||||||||||||||
CAS 号 |
1799706-65-2 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
4°C, protect from light, stored under nitrogen *该产品在溶液状态不稳定,建议您现用现配,即刻使用。 |
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : ≥ 200 mg/mL (265.27 mM) * “≥” means soluble, but saturation unknown. 配制储备液
*
请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液;该产品在溶液状态不稳定,建议您现用现配,即刻使用。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务